AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

American pharmaceutical company AbbVie has marked its entry into the Indian cancer drugs segment with Venetoclax used to ...

In Acute Myeloid Leukemia (AML), the bone marrow makes abnormal myeloblasts (a type of ... They are also developing new tests for determining prognosis — the likely course of a patient’s leukemia.

Through the launch of Venetoclax for the treatment of both Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL ...

Researchers from The University of Osaka identify a molecule that can support specific therapeutic targeting of AML with ...

The Leukemia & Lymphoma Society (LLS) announced today the first pediatric patient has received treatment in a new subtrial of ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

US drug maker AbbVie has launched its key leukemia drug, Venetoclax, in India, marking its entry into the country's oncology ...

Easily accessible tumor cells allow for real-time tumor sampling for pharmacodynamic monitoring of drug activity with minimal patient ... mutated genes in acute myeloid leukemia (AML).